Eisai's Dementia Drug, Data Fraud Scandal in Alzheimer's Research, and J&J Talc Bankruptcy Battle: Key Health Updates

In recent health news, Japanese company Eisai is developing a new dementia drug targeting tau protein for the US market by 2030. A US professor faces fraud charges for falsifying data in Alzheimer's research. Additionally, cancer victims have lost a bid to block Johnson & Johnson's proposed talc bankruptcy settlement.

Following is a summary of current health news briefs.

Japan's Eisai developing dementia drug for US market, Nikkei reports

Japanese drugmaker Eisai is developing a dementia treatment that it aims to commercialise in the U.S. by fiscal 2030, the Nikkei reported on Sunday. The new drug targets a protein called tau, which causes symptoms of Alzheimer's disease, the newspaper reported.

US professor charged with manipulating data for Alzheimer's drug trial

A U.S. medical professor has been charged with fraud for allegedly submitting false data to get millions of dollars in public funds for research into a drug to treat Alzheimer's disease. Federal prosecutors said on Friday that Hoau-Yan Wang, 67, fabricated data included in grant applications to the National Institutes of Health on behalf of himself and a publicly-listed Austin, Texas-based pharmaceutical company for which he was a consultant.

Cancer victims lose bid to block proposed J&J talc bankruptcy

A federal judge on Friday rejected a bid by a group of cancer victims to block Johnson & Johnson from pursuing a proposed bankruptcy settlement of tens of thousands of lawsuits alleging the company's baby powder and other talc products contain cancer-causing asbestos. The cancer victims sought a preliminary order in New Jersey on June 11 to preventing J&J from filing for bankruptcy outside the state, which would have effectively foiled the $6.48 billion settlement plan. The motion was part of a class action lawsuit brought by plaintiffs' lawyers opposed to the plan.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)